Impact of testosterone treatment on circulating irisin in men with late-onset hypogonadism and metabolic syndrome

The beneficial effects of testosterone replacement therapy (TRT) in men with late-onset hypogonadism (LOH) on the body composition and metabolic outcomes are well-established. A potential explanation might lie in the hormones, secreted from skeletal muscles, named "myokines". The aim of th...

Full description

Saved in:
Bibliographic Details
Published in:The aging male 2020-12, Vol.23 (5), p.1381-1387
Main Authors: Assyov, Yavor, Gateva, Antoaneta, Karamfilova, Vera, Gatev, Tsvetan, Nedeva, Iveta, Velikova, Tsvetelina, Kamenov, Zdravko Asenov
Format: Article
Language:English
Subjects:
Aging
Body composition
Endocrine therapy
Hormone Replacement Therapy
Humans
Hypogonadism - drug therapy
Irisin
late-onset hypogonadism
Male
Mens health
Metabolic syndrome
Metabolic Syndrome - drug therapy
myokines
Reproductive health
ROC Curve
Testosterone
Testosterone - therapeutic use
testosterone replacement
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The beneficial effects of testosterone replacement therapy (TRT) in men with late-onset hypogonadism (LOH) on the body composition and metabolic outcomes are well-established. A potential explanation might lie in the hormones, secreted from skeletal muscles, named "myokines". The aim of this study was to evaluate the effects of TRT on the levels of serum irisin in subjects with LOH. A total 40 men with metabolic syndrome (MS) and LOH (measured serum testosterone concentration < 12 nmol/l). TRT with Testosterone Undecanoate (Nebido™) was performed at baseline and at week 6. Irisin serum concentration was determined at baseline and at week 18 by means of ELISA. Circulating irisin was positively associated with serum testosterone (r = 0.283, p 
ISSN:1368-5538
1473-0790
DOI:10.1080/13685538.2020.1770721